A. W. Tolcher

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

A. W. Tolcher, David I. Quinn, Anna C. Ferrari et al. · Annals of Oncology · 2011 · 160 citations

Medicine, Oncology, Pharmacology +15

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Heather A. Wakelee, Amita Patnaik, Branimir I. Šikić et al. · Annals of Oncology · 2009 · 154 citations · Full text

Medicine, Oncology, Pharmacokinetics +14

A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors

A. W. Tolcher, Mace L. Rothenberg, Jordi Rodón et al. · Journal of Clinical Oncology · 2007 · 76 citations

Medicine, Oncology, Pharmacology +17

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas

Sant P. Chawla, A. W. Tolcher, Arthur P. Staddon et al. · Journal of Clinical Oncology · 2006 · 73 citations

Medicine, Oncology, Pharmacology +17

Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial

Sant P. Chawla, A. W. Tolcher, Arthur P. Staddon et al. · Journal of Clinical Oncology · 2007 · 65 citations

Medicine, Oncology, Pharmacology +15